Enanta Pharmaceuticals is a single-asset-revenue biotech in the middle of a difficult transition. Its top line is almost entirely a royalty stream on AbbVie's MAVYRET/MAVIRET regimen for hepatitis C, a mature product that has been slowly eroding for years and produced just $50.1M of revenue in the first nine months of fiscal 2026, down very slightly from a year ago. The investment case now rests on whether the company's internally developed pipeline, led by the RSV N-protein inhibitor zelicapavir and a small basket of immunology programs, can compensate for that slowing royalty before cash runs out.
The third fiscal quarter itself was a relatively quiet period on the financial side. Revenue of $14.4M was $4.0M below the prior-year quarter, reflecting continued MAVYRET/MAVIRET softness, and the net loss of $19.5M was modestly wider year over year despite R&D spending falling $5.1M. The more important developments were elsewhere. In June 2026, Enanta announced plans to begin a registrational Phase 2b/3 trial of zelicapavir in high-risk adults with RSV, and in the same month it lost a long-running patent fight against Pfizer in the U.S. Court of Appeals for the Federal Circuit, which affirmed invalidity of the company's '953 Patent covering coronavirus protease inhibitors. The Federal Circuit loss has narrowed the path for a meaningful payout from the Paxlovid litigation in the United States, although a parallel case in the Unified Patent Court of the European Union is still pending.
The clearest evidence supporting the bull case is the $62.4M nine-month R&D spend, which is now concentrated heavily on the company's own programs rather than on clinical virology work funded by AbbVie. The strongest counterargument is that zelicapavir still has to clear a Phase 2b/3 before it can generate any revenue, while MAVYRET royalties are likely to continue declining and the company is still burning roughly $30M of operating cash per year on a cash position of $211.5M. The single most important forward variable is whether the RESOLVE study, expected to dose its first patient in the fourth quarter of calendar 2026, can deliver statistically meaningful clinical benefit in a high-risk population; secondarily, the European patent decision expected after the September 29, 2026 hearing will determine whether the Paxlovid litigation has any remaining economic value. The setup is that the stock is essentially option-like, with the MAVYRET royalty providing a floor of cash inflows and the pipeline plus litigation providing two independent paths to a re-rating.